Shares of Insys Therapeutics, Inc. (NASDAQ:INSY) have earned an average rating of “Hold” from the six ratings firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $12.67.

INSY has been the topic of several research reports. Zacks Investment Research upgraded shares of Insys Therapeutics from a “sell” rating to a “strong-buy” rating and set a $15.00 price target on the stock in a research report on Wednesday, July 12th. Royal Bank Of Canada reiterated a “buy” rating and set a $16.00 price target on shares of Insys Therapeutics in a research report on Friday, April 28th. Piper Jaffray Companies downgraded shares of Insys Therapeutics from an “overweight” rating to a “neutral” rating and reduced their price target for the stock from $20.00 to $10.00 in a research report on Wednesday, May 10th. Oppenheimer Holdings, Inc. reiterated a “hold” rating on shares of Insys Therapeutics in a research report on Tuesday, July 4th. Finally, Jefferies Group LLC reiterated a “buy” rating and set a $14.00 price target on shares of Insys Therapeutics in a research report on Friday, June 9th.

In other Insys Therapeutics news, CEO Saeed Motahari bought 5,400 shares of the business’s stock in a transaction on Wednesday, June 14th. The shares were bought at an average cost of $11.10 per share, for a total transaction of $59,940.00. Following the transaction, the chief executive officer now owns 9,900 shares in the company, valued at approximately $109,890. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Rohit Vishnoi purchased 4,000 shares of the stock in a transaction dated Thursday, June 1st. The stock was bought at an average cost of $14.14 per share, with a total value of $56,560.00. Following the completion of the purchase, the director now owns 4,000 shares in the company, valued at $56,560. The disclosure for this purchase can be found here. Over the last 90 days, insiders have acquired 21,900 shares of company stock worth $268,090. Corporate insiders own 67.90% of the company’s stock.

Several hedge funds have recently made changes to their positions in INSY. Alliancebernstein L.P. boosted its stake in shares of Insys Therapeutics by 18.0% in the first quarter. Alliancebernstein L.P. now owns 61,620 shares of the specialty pharmaceutical company’s stock worth $648,000 after buying an additional 9,400 shares during the period. American International Group Inc. boosted its stake in shares of Insys Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 14,462 shares of the specialty pharmaceutical company’s stock worth $152,000 after buying an additional 953 shares during the period. Schroder Investment Management Group boosted its stake in shares of Insys Therapeutics by 36.2% in the first quarter. Schroder Investment Management Group now owns 76,894 shares of the specialty pharmaceutical company’s stock worth $845,000 after buying an additional 20,439 shares during the period. JPMorgan Chase & Co. boosted its stake in shares of Insys Therapeutics by 37.9% in the first quarter. JPMorgan Chase & Co. now owns 45,694 shares of the specialty pharmaceutical company’s stock worth $480,000 after buying an additional 12,561 shares during the period. Finally, Parametric Portfolio Associates LLC boosted its stake in shares of Insys Therapeutics by 34.5% in the first quarter. Parametric Portfolio Associates LLC now owns 25,712 shares of the specialty pharmaceutical company’s stock worth $270,000 after buying an additional 6,600 shares during the period. 28.15% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This news story was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another site, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2017/08/10/insys-therapeutics-inc-nasdaqinsy-receives-average-rating-of-buy-from-brokerages-updated-updated-updated.html.

Insys Therapeutics (NASDAQ INSY) opened at 9.07 on Monday. The company has a 50 day moving average price of $12.09 and a 200 day moving average price of $11.45. The firm’s market capitalization is $654.17 million. Insys Therapeutics has a 52-week low of $8.70 and a 52-week high of $18.80.

Insys Therapeutics (NASDAQ:INSY) last issued its quarterly earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.09) by $0.12. The business had revenue of $42.60 million for the quarter, compared to the consensus estimate of $36.90 million. Insys Therapeutics had a negative net margin of 9.63% and a negative return on equity of 3.02%. The firm’s quarterly revenue was down 38.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.13 EPS. On average, equities analysts forecast that Insys Therapeutics will post ($0.29) EPS for the current fiscal year.

Insys Therapeutics Company Profile

Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.

Receive News & Stock Ratings for Insys Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics Inc. and related stocks with our FREE daily email newsletter.